11 reports of this reaction
4.6% of all NYSTATIN AND TRIAMCINOLONE ACETONIDE reports
#2 most reported adverse reaction
PRODUCT USE IN UNAPPROVED INDICATION is the #2 most commonly reported adverse reaction for NYSTATIN AND TRIAMCINOLONE ACETONIDE, manufactured by Alembic Pharmaceuticals Inc.. There are 11 FDA adverse event reports linking NYSTATIN AND TRIAMCINOLONE ACETONIDE to PRODUCT USE IN UNAPPROVED INDICATION. This represents approximately 4.6% of all 237 adverse event reports for this drug.
Patients taking NYSTATIN AND TRIAMCINOLONE ACETONIDE who experience product use in unapproved indication should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT USE IN UNAPPROVED INDICATION is moderately reported among NYSTATIN AND TRIAMCINOLONE ACETONIDE users, representing a notable but not dominant share of adverse events.
In addition to product use in unapproved indication, the following adverse reactions have been reported for NYSTATIN AND TRIAMCINOLONE ACETONIDE:
The following drugs have also been linked to product use in unapproved indication in FDA adverse event reports:
PRODUCT USE IN UNAPPROVED INDICATION has been reported as an adverse event in 11 FDA reports for NYSTATIN AND TRIAMCINOLONE ACETONIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT USE IN UNAPPROVED INDICATION accounts for approximately 4.6% of all adverse event reports for NYSTATIN AND TRIAMCINOLONE ACETONIDE, making it one of the most commonly reported side effect.
If you experience product use in unapproved indication while taking NYSTATIN AND TRIAMCINOLONE ACETONIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.